Cue Biopharma, Inc.
CUE
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$0.70
Price-2.05%
-$0.02
1Y
Price
Market Cap
$53.884m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-282.2%
EBITDA Margin-287.1%
Net Profit Margin-116.5%
Free Cash Flow MarginRevenue
$8.287m
-10.8%
1y CAGR+133.1%
3y CAGR+76.9%
5y CAGREarnings
-$38.895m
+4.4%
1y CAGR+9.4%
3y CAGR+2.1%
5y CAGREPS
-$0.56
+22.2%
1y CAGR+27.6%
3y CAGR+19.3%
5y CAGRBook Value
$18.159m
$40.707m
Assets$22.548m
Liabilities$7.634m
DebtDebt to Assets
18.8%
-0.2x
Debt to EBITDAFree Cash Flow
-$28.320m
+22.2%
1y CAGR+12.0%
3y CAGR+7.6%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company